866930-38-3

Basic information

• Product Name: 5-bromo-2-(2-(pyrrolidin-1-yl)ethoxy)benzaldehyde
• Synonyms: 5-bromo-2-(2-(pyrrolidin-1-yl)ethoxy)benzaldehyde
• CAS NO: 866930-38-3
• Molecular Weight: 298.18
• Mol File: 866930-38-3.mol

Chemical Properties

• CAS DataBase Reference: 5-bromo-2-(2-(pyrrolidin-1-yl)ethoxy)benzaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 5-bromo-2-(2-(pyrrolidin-1-yl)ethoxy)benzaldehyde(866930-38-3)
• EPA Substance Registry System: 5-bromo-2-(2-(pyrrolidin-1-yl)ethoxy)benzaldehyde(866930-38-3)

Safety Data

• Hazardous Substances Data: 866930-38-3(Hazardous Substances Data)

Upstream product

• 7250-67-1 1-(2-chloroethyl)pyrrolidine hydrochloride 
• 1761-61-1 5-bromosalicyclaldehyde 
• 5050-41-9 N-(2-chloroethyl)-pyrrolidine 

Downstream Products

• 866930-44-1 1-[2-(2-Hydroxymethyl-4-bromophenoxy)ethyl]-pyrrolidine 

Relevant articles and documents

GPR35 MODULATORS

Described herein are GPR35 modulators and methods of using these compounds in the treatment of diseases, disorders or conditions. Also described herein are pharmaceutical compositions containing such compounds.

SUBSTITUTED AMINOPYRIDINES AND USES THEREOF

This invention relates to novel compounds having the structural formula (I) and to their pharmaceutically acceptable salt, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.

Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds

Alkyne compounds having MCH-receptor antagonistic activity, which are useful for preparing pharmaceutical compositions for the treatment of metabolic disorders and/or eating disorders, particularly obesity and diabetes.

NOVEL ALKYNE COMPOUNDS WITH AN MCH-ANTAGONISTIC ACTION AND MEDICAMENTS COMPRISING SAID COMPOUNDS

The invention relates to individual alkyne compounds with an antagonistic action against the MCH-receptor. Said compounds are suitable for producing medicaments for the treatment of metabolic disorders and/or eating disorders, in particular adiposity and diabetes.